JP2023535027A - ピルビン酸キナーゼを活性化するための組成物及び方法 - Google Patents
ピルビン酸キナーゼを活性化するための組成物及び方法 Download PDFInfo
- Publication number
- JP2023535027A JP2023535027A JP2023504298A JP2023504298A JP2023535027A JP 2023535027 A JP2023535027 A JP 2023535027A JP 2023504298 A JP2023504298 A JP 2023504298A JP 2023504298 A JP2023504298 A JP 2023504298A JP 2023535027 A JP2023535027 A JP 2023535027A
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- cycloalkyl
- heterocycle
- monocyclic
- tricyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026020484A JP2026097841A (ja) | 2020-07-21 | 2026-02-10 | ピルビン酸キナーゼを活性化するための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063054478P | 2020-07-21 | 2020-07-21 | |
| US63/054,478 | 2020-07-21 | ||
| PCT/US2021/042489 WO2022020424A1 (en) | 2020-07-21 | 2021-07-21 | Compositions and methods for activating pyruvate kinase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026020484A Division JP2026097841A (ja) | 2020-07-21 | 2026-02-10 | ピルビン酸キナーゼを活性化するための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023535027A true JP2023535027A (ja) | 2023-08-15 |
| JP2023535027A5 JP2023535027A5 (cg-RX-API-DMAC7.html) | 2024-07-03 |
Family
ID=79728915
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504298A Pending JP2023535027A (ja) | 2020-07-21 | 2021-07-21 | ピルビン酸キナーゼを活性化するための組成物及び方法 |
| JP2026020484A Pending JP2026097841A (ja) | 2020-07-21 | 2026-02-10 | ピルビン酸キナーゼを活性化するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026020484A Pending JP2026097841A (ja) | 2020-07-21 | 2026-02-10 | ピルビン酸キナーゼを活性化するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230374017A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4185293A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023535027A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116249531A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021311597B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3183980A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022020424A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024539573A (ja) * | 2021-09-30 | 2024-10-29 | シトリクス・セラピューティクス・リミテッド | 新規化合物 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12233063B2 (en) | 2017-10-20 | 2025-02-25 | The Regents Of The University Of Michigan | Compositions and methods for treating eye disorders |
| CN118434720A (zh) | 2021-12-22 | 2024-08-02 | 西特瑞治疗有限公司 | 作为丙酮酸激酶调节剂的酞嗪衍生物 |
| WO2023211999A1 (en) * | 2022-04-29 | 2023-11-02 | The Regents Of The University Of Michigan | Compositions and methods for treating eye disorders |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3173415A2 (en) * | 2008-10-09 | 2017-05-31 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Activators of human pyruvate kinase |
| WO2019035865A1 (en) * | 2017-08-15 | 2019-02-21 | Agios Pharmaceuticals Inc. | MODULATORS OF PYRUVATE KINASE AND THEIR USE |
| WO2020167976A1 (en) * | 2019-02-13 | 2020-08-20 | Agios Pharmaceuticals, Inc. | Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100137320A1 (en) * | 2008-02-29 | 2010-06-03 | Schering Corporation | Gamma secretase modulators |
| US8563580B2 (en) * | 2008-09-23 | 2013-10-22 | Georgetown University | Flavivirus inhibitors and methods for their use |
| EP2968323A4 (en) * | 2013-03-13 | 2016-12-14 | Flatley Discovery Lab | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS |
| US12233063B2 (en) * | 2017-10-20 | 2025-02-25 | The Regents Of The University Of Michigan | Compositions and methods for treating eye disorders |
-
2021
- 2021-07-21 CA CA3183980A patent/CA3183980A1/en active Pending
- 2021-07-21 US US18/017,108 patent/US20230374017A1/en active Pending
- 2021-07-21 AU AU2021311597A patent/AU2021311597B2/en active Active
- 2021-07-21 JP JP2023504298A patent/JP2023535027A/ja active Pending
- 2021-07-21 CN CN202180058558.3A patent/CN116249531A/zh active Pending
- 2021-07-21 WO PCT/US2021/042489 patent/WO2022020424A1/en not_active Ceased
- 2021-07-21 EP EP21846999.7A patent/EP4185293A4/en active Pending
-
2026
- 2026-02-10 JP JP2026020484A patent/JP2026097841A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3173415A2 (en) * | 2008-10-09 | 2017-05-31 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Activators of human pyruvate kinase |
| WO2019035865A1 (en) * | 2017-08-15 | 2019-02-21 | Agios Pharmaceuticals Inc. | MODULATORS OF PYRUVATE KINASE AND THEIR USE |
| WO2020167976A1 (en) * | 2019-02-13 | 2020-08-20 | Agios Pharmaceuticals, Inc. | Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders |
Non-Patent Citations (1)
| Title |
|---|
| CHEMINFORM, vol. 21, no. 38, JPN6025032414, 1990, pages 102 - 104, ISSN: 0005661478 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024539573A (ja) * | 2021-09-30 | 2024-10-29 | シトリクス・セラピューティクス・リミテッド | 新規化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3183980A1 (en) | 2022-01-27 |
| EP4185293A1 (en) | 2023-05-31 |
| AU2021311597B2 (en) | 2026-08-06 |
| US20230374017A1 (en) | 2023-11-23 |
| EP4185293A4 (en) | 2025-01-15 |
| JP2026097841A (ja) | 2026-06-16 |
| WO2022020424A1 (en) | 2022-01-27 |
| CN116249531A (zh) | 2023-06-09 |
| AU2021311597A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6767875B2 (ja) | Tgf−ベータ阻害剤としての2,3−二置換ピリジン化合物および使用方法 | |
| AU2019246753B2 (en) | Novel compounds and compositions for inhibition of FASN | |
| KR102797536B1 (ko) | PI3Kα 억제제 및 이의 사용 방법 | |
| CN116723843A (zh) | 用于治疗和/或预防癌症的sos1抑制剂的药物组合 | |
| CA3124678A1 (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| KR101871436B1 (ko) | 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물 | |
| CA3142340A1 (en) | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| CN116249531A (zh) | 用于激活丙酮酸激酶的组合物和方法 | |
| KR102211310B1 (ko) | [1,2,4]트라이아졸[4,3-에이]피리딘 유도체, 그의 제조 방법 또는 그의 의학적 용도 | |
| TWI601724B (zh) | 咪唑並喹啉類衍生物及其可藥用鹽、其製備方法及其在醫藥上的應用 | |
| WO2014055955A1 (en) | Gdf-8 inhibitors | |
| CN102399218A (zh) | 一类并合三杂环及其作为pi3k抑制剂的用途 | |
| JP2011525535A (ja) | PI3K/mTOR阻害剤 | |
| EP1567527A1 (en) | Condensed pyrazolo derivatives | |
| CN119013279A (zh) | 作为parp抑制剂的取代的三环类化合物及其应用 | |
| CA3129829A1 (en) | Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders | |
| TW200925160A (en) | Fused heterocyclic compound | |
| KR20140014104A (ko) | 치환된 이미다조퀴놀린 유도체 | |
| KR20230022433A (ko) | Gpr65의 조절제로서 n-(페닐아미노카보닐) 테트라하이드로-이소퀴놀린 및 관련 화합물 | |
| JP2025534283A (ja) | AhRシグナル伝達の調節に有用な化合物 | |
| HK40018685B (en) | 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer | |
| HK40018685A (en) | 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer | |
| HK1220409B (en) | 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240625 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240625 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250812 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251111 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260109 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260310 |